|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||119.72 - 123.12|
|52-week range||119.72 - 123.12|
|Beta (5Y monthly)||0.82|
|PE ratio (TTM)||42.60|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The Baylis Medical buyout is expected to expand Boston Scientific's (BSX) electrophysiology and structural heart product offerings.
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
According to Medtronic (MDT), healthcare systems are better prepared as vaccination rates continue to increase.